At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓History of MPN with ≥5% blasts in bone marrow or peripheral blood
- ✓Prior MPNs include polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, or MDS/MPN overlap
- ✓Pathology review of peripheral blood and/or bone marrow slides at study institution
- ✕Prior chemotherapy (hypomethylating agents or cytarabine-based regimens) for MPN with ≥5% blasts
- ✕Active systemic fungal, bacterial, viral, or other infection unless under treatment and controlled/stable
- ✕Known hypersensitivity to any study drug
- ✕Pregnant or breastfeeding females
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
In Brief
A Phase 2 clinical trial evaluating Decitabine, Ruxolitinib, and 4 other interventions for Acute Myeloid Leukemia and 8 related conditions. Currently recruiting, targeting 25 participants across 1 site.
Detailed Summary
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib, fedratinib, and pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Decitabine, with ruxolitinib, fedratinib, or pacritinib may work better than multi-agent chemotherapy or no pre-transplant therapy, in treating patients with accelerated/blast phase myeloproliferative neoplasms.
Study Details
Timeline
Interventions
Given IV
Given PO
Given PO
Ancillary studies
Given PO
Undergo collection of blood and bone marrow samples